Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECTIO-UC: DDR Alterations in Advanced Urothelial Cancer
NCT06820255Phase 4Recruiting
- Sponsor
- Policlinico Gemelli
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors, DNA Intercalators/Alkylators, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of cisplatin, carboplatin, gemcitabine, avelumab in urothelial carcinoma (UC), sponsored by Policlinico Gemelli. Started Jan 2025; status: recruiting.
02
Drugs
cisplatincarboplatingemcitabineavelumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06820255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06820255.